natgillin/translations-raw huggingface dataset:
Children and adolescents aged 8 years and above: Moderate to severe major depressive episode, if depression is unresponsive to psychological therapy after 4-6 sessions. 
Otroci in mladostniki stari 8 let in več: Zmerne do močno izražene hude epizode depresije, če se depresija ne odziva na psihološko zdravljenje po 4 do 6 seansah.
The list of product names concerned is given in the Annex I. The scientific conclusions are provided in the Annex II, together with the amended product information in the Annex III and the conditions of the marketing authorisations in the Annex IV. 
Seznam zadevnih imen proizvodov je naveden v Dodatku I. Znanstveni zaključki so podani v Dodatku II, skupaj s Povzetkom glavnih značilnosti zdravila v Dodatku III ter s Pogoji dovoljenja za promet z zdravilom v Dodatku IV.
The CHMP began an arbitration review for Prozac, following an application by the marketing authorisation holder to extend the indication to include the treatment of major depressive episodes in children and adolescents. 
CHMP je začel arbitražni pregled zdravila Prozac po vlogi imetnika dovoljenja za promet z zdravilom za razširitev indikacije, da bi bilo vključeno tudi zdravljenje hudih epizod depresije pri otrocih in mladostnikih.
Antidepressant medication should be offered to a child or young person with moderate to severe depression only in combination with a concurrent psychological therapy. 
Zdravljenje z antidepresivi je treba nuditi otroku ali mladi osebi z zmerno do hudo depresijo samo v kombinaciji s sočasnim psihološkim zdravljenjem.
Oral explanations were given by the Marketing Authorisation Holders on 26 April 2006. 
Ustna pojasnila so podali 26. aprila 2006.
The European Commission issued a decision on 7 January 2016. 
Evropska komisija je sklep izdala 7. januarja 2016.
This is a procedure where one Member State (the ‘reference Member State', in this instance the United Kingdom) assesses a veterinary medicine with a view to granting a marketing authorisation that will be valid in this country as well as in other Member States (the ‘concerned Member States', in this instance Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Poland, Portugal, Slovakia, Spain and The Netherlands). 
To je postopek, pri katerem ena od držav članic („referenčna država članica“, v tem primeru Združeno kraljestvo) oceni zdravilo za uporabo v veterinarski medicini glede tega, ali se zanj lahko izda dovoljenje za promet, ki bo veljavno v tej državi in drugih državah članicah („zadevnih državah članicah“, v tem primeru Avstriji, Belgiji, Češki republiki, na Danskem, v Franciji, Nemčiji, Grčiji, na Madžarskem, Irskem, v Italiji, Luksemburgu, na Poljskem, Portugalskem, Slovaškem, v Španiji in na Nizozemskem).
However, the Member States were not able to reach an agreement and the Veterinary Medicines Directorate of the United Kingdom referred the matter to the CVMP for arbitration on 28 May 2015. 
Vendar države članice niso uspele doseči soglasja, zato je direktorat za zdravila za uporabo v veterinarski medicini v Združenem kraljestvu 28. maja 2015 zadevo napotil na odbor CVMP v arbitražo.
In addition, Denmark raised a concern that the advice for prudent use in the product information is insufficient. 
Poleg tega je Danska izrazila pomislek, da nasvet o preudarni uporabi v informacijah o zdravilu ne zadošča.
The grounds for the referral were concerns raised by Denmark that the marketing authorisation of Solamocta may present a potential serious risk to human and animal health. 
Razlogi za napotitev so bili pomisleki Danske, da dovoljenje za promet z zdravilom Solamocta lahko pomeni morebitno resno tveganje za zdravje ljudi in živali.
Amoxicillin is a bactericidal antibiotic belonging to the semisynthetic penicillin group. 
Amoksicilin je baktericidni antibiotik iz skupine polsintetskih penicilinov.
The CVMP also recommended that the product information for Solamocta be amended. 
Priporočil je tudi, da se informacije o zdravilu Solamocta spremenijo.
The product is indicated for treatment of infections in chickens, turkeys and ducks caused by bacteria susceptible to amoxicillin. 
Zdravilo je indicirano za zdravljenje okužb pri piščancih, puranih in racah, ki jih povzročajo bakterije, občutljive za amoksicilin.
Denmark considered that Solamocta is essentially different from the reference product Amoxinsol 100% w/w Powder for Oral Solution and that these differences could be sufficient to require a formal bioequivalence study. 
Danska je menila, da se zdravilo Solamocta bistveno razlikuje od referenčnega zdravila Amoxinsol 100 % m/m prašek za peroralno raztopino in da lahko te razlike zadostujejo, da se zahteva izvedba uradne študije biološke enakovrednosti.
Thus the CVMP concluded that the concerns expressed by Denmark should not prevent the granting of marketing authorisations and recommended marketing authorisation be granted in the concerned Member States. 
Tako je zaključil, da pomisleki, ki jih je izrazila Danska, ne bi smeli preprečiti izdaje dovoljenj za promet z zdravilom, in priporočil, da se v zadevnih državah članicah izda dovoljenje za promet z zdravilom.
On 4 November 2015, the European Medicines Agency (the Agency) completed an arbitration procedure following a disagreement among Member States of the European Union (EU) regarding the authorisation of the veterinary medicinal product Solamocta 697 mg/g Powder for Use in Drinking Water for Chickens, Ducks and Turkeys. 
Evropska agencija za zdravila je 4. novembra 2015 zaključila arbitražni postopek po nesoglasju med državami članicami Evropske unije (EU) v zvezi z izdajo dovoljenja za promet z zdravilom za uporabo v veterinarski medicini Solamocta 697 mg/g prašek za uporabo v pitni vodi za piščance, race in purane.
Based on evaluation of the currently available data and the scientific discussion within the Committee, the CVMP concluded that a satisfactory justification has been provided that the product, Solamocta, is eligible for a waiver from the requirement to demonstrate in vivo bioequivalence with the reference product in accordance with section 7.1.c) of the CVMP guideline on the conduct of bioequivalence studies for veterinary medicinal products (EMA/CVMP/016/00-Rev.2) and that the excipients will not impact the bioavailability or safety of this product compared to the reference product. 
Na podlagi ocene trenutno razpoložljivih podatkov in znanstvene razprave v odboru CVMP je ta zaključil, da je bila podana zadovoljiva utemeljitev, da je zdravilo Solamocta upravičeno do odstopanja od zahteve za dokaz biološke enakovrednosti in vivo z referenčnim zdravilom v skladu s točko 7.1.c) Smernic CVMP o izvajanju študij biološke enakovrednosti za zdravila za uporabo v veterinarski medicini (EMA/CVMP/016/00-Rev. 2) in da pomožne snovi ne bodo vplivale na biološko uporabnost ali varnost tega zdravila v primerjavi z referenčnim zdravilom.
Solamocta contains 800 mg amoxicillin trihydrate (equivalent to 697 mg amoxicillin) as an active substance per gram product. 
Zdravilo Solamocta vsebuje 800 mg amoksicilin trihidrata (kar ustreza 697 mg amoksicilina) kot zdravilno učinkovino na gram zdravila.
The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the marketing authorisation for Solamocta can be granted provided that the recommended revised instructions on product administration and prudent use warnings are added to the product information. 
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) pri agenciji je zaključil, da se dovoljenje za promet z zdravilom Solamocta lahko izda pod pogojem, da se v informacije o zdravilu vključijo priporočena revidirana navodila o načinu dajanja zdravila in opozorila o preudarni uporabi.
Eurovet Animal Health B.V. submitted a marketing authorisation application, under Article 13(3) of Directive 2001/82/EC (i.e. hybrid or mixed application), for Solamocta to the United Kingdom via the decentralised procedure referring to the reference product Amoxinsol 100% w/w Powder for Oral Solution authorised in the United Kingdom. 
je po decentraliziranem postopku v Združenem kraljestvu predložilo vlogo za pridobitev dovoljenja za promet z zdravilom Solamocta v skladu s členom 13(3) Direktive 2001/82/ES (tj. hibridno ali mešano vlogo), ki se nanaša na referenčno zdravilo Amoxinsol 100 % m/m prašek za peroralno raztopino, odobreno v Združenem kraljestvu.
The Committee recommended revised instructions on product administration and advice on prudent use to address responsible use in relation to development of antimicrobial resistance. 
Da bi spodbudil odgovorno uporabo v zvezi z razvojem protimikrobne odpornosti, je odbor priporočil revidirana navodila za dajanje zdravila in nasvet o preudarni uporabi.
Why was Solamocta 697 mg/g Powder for Use in Drinking Water for Chickens, Ducks and Turkeys reviewed? 
Zakaj je bil opravljen pregled zdravila Solamocta 697 mg/g prašek za uporabo v pitni vodi za piščance, race in purane?
What is Solamocta 697 mg/g Powder for Use in Drinking Water for Chickens, Ducks and Turkeys? 
Kaj je zdravilo Solamocta 697 mg/g prašek za uporabo v pitni vodi za piščance, race in purane?
Questions and answers on Solamocta 697 mg/g Powder for Use in Drinking Water for Chickens, Ducks and Turkeys (amoxicillin trihydrate) 
Vprašanja in odgovori v zvezi z zdravilom Solamocta 697 mg/g prašek za uporabo v pitni vodi za piščance, race in purane (amoksicilin trihidrat)
It usually disappeared spontaneously within 1 week at most. 
Običajno je spontano izginila v največ enem tednu.
After reconstitution, each dose of 1 ml contains: 
Po rekonstituciji vsak odmerek (1 ml) vsebuje:
Date of first authorisation: 03/05/2013 Date of last renewal: 20/03/2018 
Datum pridobitve dovoljenja za promet: 03/05/2013 Datum zadnjega podaljšanja dovoljenja za promet: 20/03/2018
Efficacy of the treatment has not been investigated beyond 2 years following treatment. 
Učinkovitost zdravljenja ni bila raziskana po preteku 2 let od zdravljenja.
ATC-vet code: QL03AX90. 
Oznaka ATC vet: QL03AX90.
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon 
Če opazite kakršne koli resne stranske učinke ali druge učinke, tudi tiste, ki niso navedeni v tem navodilu za uporabo ali mislite da zdravilo ni delovalo, obvestite svojega veterinarja.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (http://www.ema.europa.eu/). 
Podrobne informacije o tem zdravilu za uporabo v veterinarski medicini so na voljo na spletni strani Evropske agencije za zdravila (http://www.ema.europa.eu/.)
This was demonstrated in a field trial over a period of 2 years. 
To je bilo potrjeno s terensko študijo v trajanju 2 let.
The virus expresses the IL-2 gene at the inoculation site, but does not replicate in the cat. 
Virus izraža IL-2 gen na mestu inokulacije, vendar se v mački ne replicira.
Efficacy has only been tested in conjunction with surgery and radiotherapy; therefore the treatment should be conducted according to treatment course described in section 4.9. 
Učinkovitost je bila preskušena le v povezavi z operativnim zdravljenjem in radioterapijo, zato je potrebno zdraviti v skladu s potekom zdravljenja, opisanim v poglavju 4.9.
Start the treatment course the day before radiation therapy, preferably within one month after surgical excision. 
Zdravljenje začnite dan pred zdravljenjem z obsevanjem, če je le mogoče v enem mesecu po kirurški odstranitvi tumorja.
A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND 
A. IZDELOVALCI PROIZVAJALCI BIOLOŠKE ZDRAVILNE UČINKOVINE IN
Shelf life after first opening the immediate packaging: use immediately after reconstitution. 
Rok uporabnosti po prvem odpiranju stične ovojnine: Uporabite takoj po rekonstituciji.
Lyophilisate: whitish homogeneous pellet. 
Liofilizat: belkasta homogena peleta.
Mild local and/or systemic adverse reactions related to the injection itself may be observed transitorily. 
Občasno se lahko prehodno pojavijo blagi lokalni in/ali sistemski neželeni učinki povezani s samim injiciranjem.
Canarypox recombinants are known to be safe for humans. 
Rekombinantni pox virus kanarčkov je varen za ljudi.
As safety and efficacy of repetition of the treatment to treat fibrosarcoma recurrence have not been investigated, repetition of the treatment should be considered by the veterinarian taking into account the benefit-risk balance. 
Ker varnost in učinkovitost ponovnega zdravljenja za preprečevanje ponovitve fibrosarkoma ni bilo raziskano, mora o ponovnem zdravljenju odločati veterinar na osnovi ocene razmerja med koristjo in tveganjem.
The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports). 
Pogostost neželenih učinkov je določena po naslednjem dogovoru: zelo pogosti (neželeni učinki se pokažejo pri več kot 1 od 10 zdravljenih živali) pogosti (pri več kot 1, toda manj kot 10 živali od 100 zdravljenih živali) občasni (pri več kot 1, toda manj kot 10 živali od 1.000 zdravljenih živali) redki (pri več kot 1, toda manj kot 10 živali od 10.000 zdravljenih živali) zelo redki (pri manj kot 1 živali od 10.000 zdravljenih živali, vključno s posameznimi primeri).
Treatment course: 4 administrations at 1-week intervals (day 0, day 7, day 14, day 21) followed by 2 administrations at 2-week intervals (day 35, day 49). 
Potek zdravljenja: 4 odmerki v razmakih 1 tedna (dan 0, dan 7, dan 14 in dan 21), ki jim sledita 2 odmerka v razmaku 2 tednov (dan 35 in dan 49).
Collagen hydrolysate Casein hydrolysate Sodium chloride 
Hidrolizat kolagena Hidrolizat kazeina Natrijev klorid
Moreover feline IL-2 has been shown to have very low biological activity on human leukocytes compared to human IL-2. 
Še več, mačji IL-2 ima v primerjavi s človeški IL-2 dokazano zelo nizko biološko aktivnost na človeške levkocite.
Efficacy has not been tested in cats with metastasis or lymph node involvement. 
Učinkovitost ni bila preskušena pri mačkah z metastazami ali razširjenostjo bolezni na bezgavke.
After two years of study follow-up, Oncept IL-2 treated cats showed a longer median time to relapse (above 730 days) compared to control cats (287 days). 
Po dveh letih po študiji, je bil povprečni čas do ponovitve bolezni pri mačkah, zdravljenih z Oncept IL-2, daljši (nad 730 dni) v primerjavi s kontrolno skupino (287 dni).
After reconstitution of the lyophilisate with the solvent, shake gently and administer five injections (each approximately 0.2 ml) around the tumour excision site: one injection at each corner and one injection at the centre of a 5 cm x 5 cm square centred on the middle of the surgical scar. 
Po rekonstituciji liofilizata z vehiklom nežno pretresite in okrog mesta odstranitve tumorja 5-krat injicirajte zdravilo (po približno 0,2 ml); ena injekcija v vsakem kotu in ena injekcija na v centru 5 cm x 5 cm velikega kvadrata, lociranega na sredino kirurške brazgotine.
EXP {month/year} Use immediately after reconstitution. 
EXP {mesec/leto} Po rekonstituciji uporabite takoj.
Lyophilisate: 6 x 1 dose Solvent: 6 x 1 ml 
Liofilizat 6 x 1 odmerek Vehikel 6 x 1 ml
Name and address of the manufacturer of the biological active substance 
Ime in naslov proizvajalcev biološke učinkovine
Solvent: Water for injections. 
Vehikel: Voda za injiciranje
Disodium phosphate dihydrate Potassium dihydrogen phosphate. 
Natrijev dihidrogenfosfat dihidrat Kalijev dihidrogenfosfat
A decision to use this immunological veterinary medicinal product before or after any other veterinary medicinal product therefore needs to be made on a case by case basis. 
Zato se za uporabo tega imunološkega zdravila pred ali po uporabi katerega koli drugega zdravila za uporabo v veterinarski medicini odločamo od primera od primera.
Pharmacotherapeutic group: Antineoplastic and immunomodulating agents, other immunostimulants. 
Farmakoterapevtska skupina: Zdravila z delovanjem na novotvorbe in imunomodulatorji, druga zdravila za spodbujanje imunske odzivnosti.
Specific mechanisms by which immunostimulation induces anti-tumoural activity is not known. 
Specifični mehanizmi s katerimi imunostimulacija inducira protitumorsko delovanje, niso znani.
Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the veterinary medicinal product. 
Ne mešajte z nobenim drugim zdravilom za uporabo v veterinarski medicini, razen z vehiklom, ki je priložen za uporabo s tem zdravilom za uporabo v veterinarski medicini.
Do not use this veterinary medicinal product after the expiry date which is stated on the label after EXP. 
Zdravila ne smete uporabljati po datumu izteka roka uporabnosti, navedenega na ovojnini.
Immunotherapy to be used in addition to surgery and radiotherapy in cats with fibrosarcoma (2-5 cm diameter) without metastasis or lymph node involvement in order to reduce the risk of relapse and to increase the time to relapse (local recurrence or metastasis). 
Imunoterapija kot dodatna terapija operativnimu zdravljenjemu in radioterapiji pri mačkah s fibrosarkomom (2-5 cm v premeru) brez metastaz ali prizadetosti bezgavk, da se za zmanjša nevarnost povrnitve bolezni in podaljša časa do povrnitve bolezni (lokalna ponovitev ali metastaza).
Overdose (symptoms, emergency procedures, antidotes): 
Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi) (če je potrebno):
Oncept IL-2 injected into the tumour bed thus delivers in situ a low dose of feline interleukin-2, which stimulates antitumour immunity while avoiding toxicity associated with systemic treatment. 
Oncept IL-2 tako zagotovi in situ nizek odmerek mačjega interleukina-2, ki stimulira protitumorsko imunost ter brez toksičnosti, ki je lahko posledica sistemskega dajanja.
Store in the original package in order to protect from light. 
Zaščitite pred svetlobo.
SC Read the package leaflet before use. 
SC Pred uporabo preberite navodilo za uporabo.
Oncept IL-2 treatment reduced the risk of relapse, from 6 months after the start of treatment, by approximately 56% after 1 year and 65% after 2 years. 
6 esecev po začetku zdravljenja za približno 56% po 1 letu in 65% po dveh letih.
After reconstitution use immediately. 
Uporabite takoj po rekonstituciji.
The vaccine strain vCP1338 is a recombinant canarypox virus expressing feline interleukin-2 (IL-2). 
Cepni sev vCP1338 je rekombinantni poxvirus kanarčkov, ki izraža mačji interleukin-2 (IL-2).
Oncept IL-2 lyophilisate 
Oncept IL-2 Liofilizat
For the full list of excipients, see section 6.1. 
*ELISA infektivni odmerek 50% Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
A moderate local reaction (pain on palpation, swelling, scratching) occurred very commonly in safety studies. 
Zelo pogosto se je v študijah varnosti pojavila zmerna lokalna reakcija (bolečina na otip, oteklina in srbenje).
After the administration of an overdose (10 doses), transient moderate to marked hyperthermia, as well as local reactions (swelling, erythema or slight pain, and in some cases, heat at the injection site) may occur. 
Po dajanju prevelikega odmerka (10 odmerkov), se lahko pojavijo prehodno zmerno do močneje povišana telesna temperatura, lahko pa tudi lokalne reakcije (oteklina, eritem ali rahla bolečina in v nekaterih primerih toplota na mestu injiciranja).
Oncept IL-2 lyophilisate and solvent for suspension for injection for cats 
Oncept IL-2 liofilizat in vehikel za suspenzijo za injiciranje za mačke
Efficacy has only been tested in conjunction with surgery and radiotherapy; therefore the treatment should be conducted according to treatment course described in section “Dosage for each species, route and method of administration”. 
Učinkovitost je bila preskušena le v povezavi z operativnim zdravljenjem in radioterapijo, zato je potrebno zdraviti v skladu s potekom zdravljenja, ki je opisan v poglavju « ODMERKI ZA
Use of the recommended mode of administration in 5 injection points is important for achieving efficacy of the product; injection in 1 point may lead to reduced efficacy (see section 4.9). 
pri injiciranju na enem mestu lahko pride do manjše učinkovitosti (glejte poglavje 4.9).
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Cardboard box of 6 vials of lyophilisate and 6 vials of solvent 
PODATKI NA ZUNANJI OVOJNINI Škatla s 6 vialami liofilizata in 6 vialami vehikla
Solvent for Oncept IL-2 
Vehikel za Oncept IL-2
Transient apathy and hyperthermia (above 39.5 °C) occurred commonly in field studies. 
Lahko se pojavita prehodna apatija in povišana telesna temperatura (nad 39° C).
Name and address of the manufacturer responsible for batch release 
Ime in naslov proizvajalcazdravila odgovornega za sproščanje serije
Cardboard box containing 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent. 
Škatla s 6 vialami liofilizata in 6 vialami vehikla.
In a randomized clinical study, cats from different origins presenting a fibrosarcoma without metastasis or lymph node involvement were included in two groups, one receiving the reference treatment - surgery and radiotherapy - and the other receiving Oncept IL-2 in addition to surgery and radiotherapy. 
V klinični študiji so bile mačke različnega izvora s fibrosarkomom brez metastaz in prizadetosti limfnih žlez, razdeljene v dve skupini.
Type I glass vial with a butyl elastomer closure, sealed with an aluminium cap. Cardboard box of 6 vials of 1 dose of lyophilisate and 6 vials of 1 ml of solvent. 
Viala iz stekla tipa I z butilelastomerno zaporko, zapečateno z aluminijastim pokrovčkom.
Feline interleukin-2 recombinant canarypox virus (vCP1338) ........................................ ≥ 106.0 EAID50 
Rekombinantni pox virus kanarčkov (vCP1338), ki vsebuje mačji interleukin-2.............≥ 106.0 EAID*50
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
PRILOGA II A. PROIZVAJALCI BIOLOŠKE UČINKOVINE IN PROIZVAJALEC ZDRAVILA,
QUANTITY OF THE ACTIVE SUBSTANCE(S) 
C. NAVEDBA NAJVIŠJIH DOVOLJENIH KOLIČIN OSTANKOV ZDRAVILA (MRL)
Lyophilisate and solvent for suspension for injection 
liofilizat in vehikel za suspenzijo za injiciranje za mačke
Active substance: 
KOLIČINA UČINKOVINE
However, the low number of patients involved and other serious shortcomings in the design of the studies prevented any firm conclusions being drawn. 
Vendar zaradi nizkega števila vključenih bolnikov in drugih resnih pomanjkljivosti pri zasnovi študij ni bilo možno sprejeti trdnih zaključkov.
Passion flower EMA/275240/2014 
Zel zdravilne pasijonke EMA/275240/2014
Passion flower medicines should only be used in adults and adolescents over the age of 12 years. 
Zdravila, ki vsebujejo zel zdravilne pasijonke, se smejo uporabljati samo pri odraslih in mladostnikih, starejših od 12 let.
This summary is not intended to provide practical advice on how to use medicines containing passion flower. 
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o uporabi zdravil, ki vsebujejo zel zdravilne pasijonke.
Passion flower is the common name for the above-ground parts of the plant Passiflora incarnata L. The HMPC conclusions only cover passion flower preparations which are obtained by comminuting (reducing into tiny pieces) or powdering the dried above-ground parts or as dry and liquid extracts. 
Zel zdravilne pasijonke je splošno ime za nadzemne dele rastline Passiflora incarnata L. Zaključki odbora HMPC zajemajo samo pripravke z zeljo zdravilne pasijonke, ki se pridobivajo z drobljenjem (zmanjševanjem na majhne delce) ali z drobljenjem posušenih nadzemnih delov v prah ter kot suhi ali tekoči ekstrakti.